Pacira Pharma's (PCRX) Exparel Could Be $1 Billion Product

Pacira Pharmaceuticals (NASDAQ: PCRX) presented at Jefferies' London conference. During the presentation, it highlighted strong momentum in November Exparel sales.

"The stock pulled back as Q3 sales of $4.6M were a little light, but now seems an ideal re-entry point," said analyst Corey Davis.

During the presentation, Pacira made the point that a 10 percent penetration of the 40 million relevant surgical procedures would make Exparel a $1 billion product.

Jefferies has a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX) with a price target of $22.00.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $15.27 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Truist Securities Reinstates Pacira Pharmaceuticals (PCRX) at Buy
• Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30